Literature DB >> 12363457

Tamoxifen ("Nolvadex"): a review.

M Clemons1, S Danson, A Howell.   

Abstract

Tamoxifen has been used in the management of breast cancer for over 30 years. Since its introduction for the treatment of advanced breast cancer, its indications have increased to include the treatment of early breast cancer, ductal carcinoma in situ, and more recently for breast cancer chemoprevention. Tamoxifen has a good tolerability profile and moreover, unlike many other endocrine therapies, it is efficacious in both pre- and postmenopausal women. It is the combination of efficacy and tolerability that allows tamoxifen to maintain its position as the hormonal treatment of choice for most patients with oestrogen-receptor positive breast cancer. Ongoing studies will provide further information about the optimal duration of tamoxifen therapy and how it compares with the newer aromatase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12363457     DOI: 10.1016/s0305-7372(02)00036-1

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  39 in total

1.  Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkers.

Authors:  Jeffrey R Whiteaker; Lei Zhao; Heidi Y Zhang; Li-Chia Feng; Brian D Piening; Leigh Anderson; Amanda G Paulovich
Journal:  Anal Biochem       Date:  2006-12-20       Impact factor: 3.365

2.  PI3-kinase/p38 kinase-dependent E2F1 activation is critical for Pin1 induction in tamoxifen-resistant breast cancer cells.

Authors:  Kwang Youl Lee; Jeong Woon Lee; Hyun Jeong Nam; Jeong-Hyun Shim; Youngsup Song; Keon Wook Kang
Journal:  Mol Cells       Date:  2011-05-11       Impact factor: 5.034

Review 3.  Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression.

Authors:  Priya Bhardwaj; CheukMan C Au; Alberto Benito-Martin; Heta Ladumor; Sofya Oshchepkova; Ruth Moges; Kristy A Brown
Journal:  J Steroid Biochem Mol Biol       Date:  2019-03-06       Impact factor: 4.292

4.  Toremifene and tamoxifen have similar efficacy in the treatment of patients with breast cancer: a meta-analysis of randomized trials.

Authors:  Qian-Ling Ye; Zhi-Min Zhai
Journal:  Mol Biol Rep       Date:  2014-01-04       Impact factor: 2.316

5.  Triptolide inhibits human breast cancer MCF-7 cell growth via downregulation of the ERα-mediated signaling pathway.

Authors:  Han Li; Guo-feng Pan; Zhen-zhou Jiang; Jing Yang; Li-xin Sun; Lu-yong Zhang
Journal:  Acta Pharmacol Sin       Date:  2015-04-13       Impact factor: 6.150

6.  Combination of siRNA-directed gene silencing with epigallocatechin-3-gallate (EGCG) reverses drug resistance in human breast cancer cells.

Authors:  Mohammad Ali Esmaeili
Journal:  J Chem Biol       Date:  2015-08-08

7.  Treatment-related risk factors for arm lymphedema among long-term breast cancer survivors.

Authors:  Nandita Das; Richard N Baumgartner; Elizabeth C Riley; Christina M Pinkston; Dongyan Yang; Kathy B Baumgartner
Journal:  J Cancer Surviv       Date:  2015-04-26       Impact factor: 4.442

Review 8.  Postmenopausal Breast Cancer, Aromatase Inhibitors, and Bone Health: What the Surgeon Should Know.

Authors:  K J Baatjes; J P Apffelstaedt; M J Kotze; M Conradie
Journal:  World J Surg       Date:  2016-09       Impact factor: 3.352

9.  Tamoxifen induces expression of immune response-related genes in cultured normal human mammary epithelial cells.

Authors:  Laura J Schild-Hay; Tarek A Leil; Rao L Divi; Ofelia A Olivero; Ainsley Weston; Miriam C Poirier
Journal:  Cancer Res       Date:  2009-01-20       Impact factor: 12.701

10.  Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro.

Authors:  H Michael; P L Härkönen; L Kangas; H K Väänänen; T A Hentunen
Journal:  Br J Pharmacol       Date:  2007-04-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.